Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2426454
Max Phase: Preclinical
Molecular Formula: C32H44N2O8S
Molecular Weight: 616.78
Molecule Type: Small molecule
Associated Items:
ID: ALA2426454
Max Phase: Preclinical
Molecular Formula: C32H44N2O8S
Molecular Weight: 616.78
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@@H]2CCC[C@@H]3O[C@H]4OCC[C@H]4[C@@H]32)cc1
Standard InChI: InChI=1S/C32H44N2O8S/c1-21(2)19-34(43(37,38)24-14-12-23(39-3)13-15-24)20-27(35)26(18-22-8-5-4-6-9-22)33-32(36)42-29-11-7-10-28-30(29)25-16-17-40-31(25)41-28/h4-6,8-9,12-15,21,25-31,35H,7,10-11,16-20H2,1-3H3,(H,33,36)/t25-,26-,27+,28-,29+,30-,31+/m0/s1
Standard InChI Key: ORJPZJYXIFRPSW-XRRZKTRZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 616.78 | Molecular Weight (Monoisotopic): 616.2818 | AlogP: 3.97 | #Rotatable Bonds: 12 |
Polar Surface Area: 123.63 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.57 | CX Basic pKa: | CX LogP: 4.24 | CX LogD: 4.24 |
Aromatic Rings: 2 | Heavy Atoms: 43 | QED Weighted: 0.37 | Np Likeness Score: 0.19 |
1. Ghosh AK, Parham GL, Martyr CD, Nyalapatla PR, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.. (2013) Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies., 56 (17): [PMID:23947685] [10.1021/jm400768f] |
Source(1):